Sarepta Therapeutics Inc
NASDAQ:SRPT

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
NASDAQ:SRPT
Watchlist
Price: 22.32 USD 1.45%
Market Cap: 2.3B USD

Intrinsic Value

The intrinsic value of one SRPT stock under the Base Case scenario is 57.06 USD. Compared to the current market price of 22.32 USD, Sarepta Therapeutics Inc is Undervalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SRPT Intrinsic Value
57.06 USD
Undervaluation 61%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Sarepta Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about SRPT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SRPT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Sarepta Therapeutics Inc.

Explain Valuation
Compare SRPT to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Concerns remain over the company’s heavy reliance on its Duchenne muscular dystrophy (DMD) portfolio; any setback in its lead gene therapy program or regulatory pushback on existing therapies could have a disproportionately negative impact on overall revenue prospects.

The FDA’s historically mixed feedback on Sarepta’s products, such as eteplirsen, underscores ongoing regulatory uncertainty; further scrutiny or demands for additional data could delay commercialization and increase costs.

Competition from other biopharmaceutical companies pursuing next-generation gene therapies for rare neuromuscular disorders poses a threat to Sarepta’s market share, given that some competitors have robust research pipelines and stronger commercial infrastructure.

Bull Theses

Sarepta’s leadership in precision genetic medicine for DMD, underpinned by multiple RNA-targeted therapies already on the market and an advancing gene therapy program, positions it at the forefront of treatment innovation for a high-need patient population.

The company’s extensive collaboration network and partnerships, including relationships with academic institutions and larger pharma firms, help mitigate research and development risks while broadening its pipeline beyond DMD into other neuromuscular indications.

Substantial progress in gene-editing and gene-replacement technologies could further cement Sarepta’s reputation as a leading innovator, allowing the firm to leverage its manufacturing expertise for potential expansion into additional rare disease markets.

Show More Less
How do you feel about SRPT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sarepta Therapeutics Inc

Current Assets 2.7B
Cash & Short-Term Investments 851m
Receivables 541.6m
Other Current Assets 1.3B
Non-Current Assets 771.1m
Long-Term Investments 9.2m
PP&E 498.1m
Intangibles 29.7m
Other Non-Current Assets 234.1m
Current Liabilities 921.4m
Accounts Payable 94m
Accrued Liabilities 157.7m
Other Current Liabilities 669.7m
Non-Current Liabilities 1.3B
Long-Term Debt 1B
Other Non-Current Liabilities 216.7m
Efficiency

Free Cash Flow Analysis
Sarepta Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Sarepta Therapeutics Inc

Revenue
2.4B USD
Cost of Revenue
-573.2m USD
Gross Profit
1.8B USD
Operating Expenses
-1.9B USD
Operating Income
-86m USD
Other Expenses
-185.5m USD
Net Income
-271.5m USD
Fundamental Scores

SRPT Profitability Score
Profitability Due Diligence

Sarepta Therapeutics Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
ROE is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
33/100
Profitability
Score

Sarepta Therapeutics Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

SRPT Solvency Score
Solvency Due Diligence

Sarepta Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
37/100
Solvency
Score

Sarepta Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SRPT Price Targets Summary
Sarepta Therapeutics Inc

Wall Street analysts forecast SRPT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SRPT is 30.15 USD with a low forecast of 5.05 USD and a high forecast of 194.25 USD.

Lowest
Price Target
5.05 USD
77% Downside
Average
Price Target
30.15 USD
35% Upside
Highest
Price Target
194.25 USD
770% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Sarepta Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SRPT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SRPT Insider Trading
Buy and sell transactions by insiders

SRPT News

Other Videos
What is the Intrinsic Value of one SRPT stock?

The intrinsic value of one SRPT stock under the Base Case scenario is 57.06 USD.

Is SRPT stock undervalued or overvalued?

Compared to the current market price of 22.32 USD, Sarepta Therapeutics Inc is Undervalued by 61%.

Back to Top